https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-10-01 / APMIS 2006 Oct;114(10):731-43
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-10-01 / APMIS 2006 Oct;114(10):731-432006-10-01 00:00:002006-10-01 00:00:00Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-08-01 / J. Virol. 2006 Aug;80(15):7522-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-08-01 / J. Virol. 2006 Aug;80(15):7522-342006-08-01 00:00:002019-02-15 09:22:12Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-382006-07-15 00:00:002020-06-23 09:36:30Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-04-15 / Clin. Cancer Res. 2006 Apr;12(8):2555-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-04-15 / Clin. Cancer Res. 2006 Apr;12(8):2555-622006-04-15 00:00:002019-02-15 09:22:14A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-03-01 / Coll Antropol 2006 Mar;30(1):185-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-03-01 / Coll Antropol 2006 Mar;30(1):185-92006-03-01 00:00:002019-02-15 09:22:15Combined action of virus injection and local tumor irradiation on tumor growth in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-672006-02-01 00:00:002020-06-23 09:36:57A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Expert Opin Biol Ther 2005 Dec;5(12):1627-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Expert Opin Biol Ther 2005 Dec;5(12):1627-332005-12-01 00:00:002019-02-15 09:22:16Virus-based therapies for colon cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-28 / Mol. Ther. 2006 Jan;13(1):221-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-28 / Mol. Ther. 2006 Jan;13(1):221-82005-10-28 00:00:002019-02-15 09:00:17Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-842005-08-01 00:00:002020-06-23 09:37:35Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-06-01 / Zhonghua Gan Zang Bing Za Zhi 2005 Jun;13(6):467-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-06-01 / Zhonghua Gan Zang Bing Za Zhi 2005 Jun;13(6):467-82005-06-01 00:00:002019-02-15 09:22:19[Study of Newcastle disease virus killing hepatocellular carcinoma cells in vitro]
